


Computational Toxicology and Prenatal Development

Thomas B. Knudsen
National Center for Computational Toxicology



The views expressed in this presentation are those of the author[s] and do not necessarily reflect the views or policies of the U.S. Environmental Protection Agency.

Embryogenesis: orchestration of cellular complexity

EMBRYONIC CELL BEHAVIORS

cell growth & death

differentiation & function

cell motility & adhesion

clocks & organizers

genetic signals & responses

ECM synthesis & remodeling

CONSEQUENCES OF DISRUPTION

incorrect cell number

missing cell types

disorganization

chaos and ataxia

dysregulation


loss of mechanical properties



Systems models

- ❖ **ToxCast/Tox21:** HTS paradigm enables data-driven chemical prioritization and the capacity for predictive toxicology
- ❖ **Need:** computational models that reconstruct the dynamics and mechanics of diverse tissues and complex *in vivo* systems
- ❖ **Cell networks:** predicting cell-level behavior is complex enough without the emergent potential of a multicellular system
- ❖ **Goal:** develop and use cell agent-based models to help inform prioritization, evaluate mechanisms, and predict toxicity

ToxCast DevTox model



Prenatal models

❖ general idea to mine signatures of DevTox from ToxCast/Tox21 data

- find significant **univariate** features (single assay feature to DEV endpoint)
- build **multivariate** signatures (multiple features to DEV endpoint)
- map features to known pathways, processes, phenotypes

❖ predictive DevTox models completed with ToxCast Phase-I data

rat-rabbit prenatal ToxRefDB: Sipes et al. 2011, Toxicol Sci (in press)


mESC differentiation: Chandler et al. 2011, PLoS One 6(6): e18540

angiogenesis: Kleinstreuer et al. 2011, Env Hlth Persp (in press)

zebrafish development: Padilla et al. (submitted)


zebrafish concordance: Sipes et al. 2011, Birth Defects Res C (in press)

- ❖ ToxCastDB: AC50s for 309 Phase-I chemicals for 662 *in vitro* features
- ❖ ToxRefDB: 17 endpoints in pregnant rats (251) and rabbits (234)
- ❖ assays aggregated and reduced by genes/pathways/processes
- ❖ linear model assessment with five-fold cross-validation on 80/20 split



Global prenatal model

Model predicts DevTox in rats with >70% BA



Model predicts DevTox in rabbits with >70% BA

Train BA: 0.71 ± 0.01
Test BA: 0.70 ± 0.09

Train BA: 0.75 ± 0.02
Test BA: 0.71 ± 0.03

Similar features between models


Rat Feature	Individual Assay	Weight	p-value
RAR	ATG_RARa_TRANS	0.58	8.37E-02
	ATG_RARb_TRANS		
	NVS_NR_hRAR_Antagonist		
GPCR	NVS_GPCR_hPY2	0.55	8.08E-03
	NVS_GPCR_hOpiate_mu		
	NVS_GPCR_hORL1		
	NVS_GPCR_hM1		
TGFβ	ATG_TGFb_CIS	0.38	6.34E-03
	BSK_BE3C_TGFb1_down		
MT	CLM_MicrotubuleCSK_Destabilizer_24hr	0.30	1.74E-02
SENS_CYP	CLZD_CYP1A1_48	0.26	5.19E-03
	CLZD_CYP2B6_48		
AP1	ATG_AP_1_CIS	0.24	1.70E-01
SLCO1B1	CLZD_SLCO1B1_48	0.11	1.29E-02
CYP	NVS_ADME_rCYP2A2	0.06	3.22E-03
	NVS_ADME_rCYP2B1		
HLA-DR	BSK_BE3C_hLADR_up	-0.38	2.13E-02
PXR	ATG_PXR_TRANS	-0.24	2.06E-01
	NCGC_PXR_Agonist_human		
IL8	BSK_LPS_IL8_down	-0.23	1.36E-01
	BSK_SAg_IL8_down		
PGE2	BSK_LPS_PGE2_down	-0.18	4.25E-02

Rabbit Feature	Individual Assay	Weight	p-value
CCL2	BSK_3C_MCP1_up	1.15	1.5E-06
	BSK_SM3C_MCP1_up		
	BSK_SAg_MCP1_up		
	BSK_LPS_MCP1_up		
IL	BSK_KF3CT_MCP1_up	0.39	3.9E-03
	BSK_BE3C_IL1a_up		
CYP	BSK_LPS_IL1a_up	0.24	4.6E-03
	BSK_LPS_IL8_up		
TGFβ	CLZD_CYP1A1_24	0.28	1.0E-01
	NVS_ADME_rCYP2A2		
MESC	BSK_BE3C_TGFb1_up	0.13	8.6E-02
	BSK_BE3C_TGFb1_down		
SULT2A1	MESC_CellCount_AC50_Down	-0.26	4.1E-04
	MESC_MHC_AC50_Down		
PGE2	CLZD_SULT2A1_6	-0.15	2.4E-02
	BSK_LPS_PGE2_down	-0.15	2.4E-02




Positive predictors
Negative predictors

Prioritization

Rat





Rabbit





Features mapped by GO-process

univariate DevTox features
multivariate DevTox features




HTS detected pathway


ToxRefDB_prenatal






mESC growth & differentiation





angiogenesis




Angiogenesis & Vascular disruption



Cell-agent-based models



CompuCell3D.org




- stochastic cellular behaviors
- specified cellular activities
- PDE solvers for biochemical gradients
- toolbox of morphogenetic processes
- executes collective cell behavior
- enables emergent properties

Simple CC3D model




macrophage navigating RBCs
toward a microbial pathogen




simple CompuCell3D model

Angiogenesis is more complex




Angiogenic field at time=0




Virtual angiogenesis


**VEGF
165**




**Ang1/
Tie2**




MMPs




CXCL10




**VEGF
121**



CCL2



sFlt1



Normal phenotype

Vascular tree, 2-day quail embryo (A,B)

[Herrero and Kohn (2009) *M³AS*]

CC3D Simulation Results (C,D)



Endothelial Stalk




Endothelial Tip



Mural Cell



Inflammatory Cell







In situ


In silico

**VEGF
gradient**

Emergence


Time →

-  **Endothelial Stalk**
-  **Endothelial Tip**
-  **Mural Cell**
-  **Inflammatory Cell**



In silico


**Emergence
(bridging)**



In vitro

[Fentin et al. (2010) Blood]

TEST CASE: Thalidomide and 5HPP-33




TEST CASE: Thalidomide and 5HPP-33


In vitro

SOURCE: Noguchi et al. 2005, Bioorg Med Chem Lett. 15 :5509-13. (experimental, 100 uM)


control



Thalidomide






5HPP-33





In silico

SOURCE: Kleinstreuer et al. 2011, in preparation (ToxCastDB, 40 uM)




quantitative prediction
emergent from ToxCast
HTS data input (AC50s)




Integration (in progress)


Chick limb




+CPS49



Virtual limb



PCD in AER



Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation

Christina Therapontos^{a,b}, Lynda Erskine^b, Erin R. Gardner^c, William D. Figg^d, and Neil Vargesson^{a,b,1}

Rountree et al., 2011
(in preparation)

Therapontos et al. PNAS 106: 8573-8578, 2009

Application to ToxCast

endothelial connectivity (plexus), in-degree (branching), vessel uniformity (width), sprouting


weakened mural adhesion to nascent vessels; altered endothelial growth and spreading behavior, lack of sprouting due to Flt1 inhibition

endothelial hyperplasia with decreased cell migration and polarization possibly due to increased uPAR – enhances ECM locking


little to no vessel formation





control




ToxC-P




ToxC-T



ToxC-Y



Virtual mixture



Summary

- ❖ **Goal:** applying HTS data, *in silico* tools, and models to look globally at developmental processes and toxicities in a new way
- ❖ **Approach:** predictive and mechanistic models that dynamically integrate data with relevant information about embryonic systems
- ❖ **Virtuomics:** run ‘what-if’ scenarios to predict adverse outcomes from different perturbations (chemicals, concentrations, mixtures)
- ❖ **Benefit:** scientifically-based predictions on how development might be affected across a range of complex factors

<http://www.epa.gov/ncct/v-Embryo/>



Acknowledgements

<http://www.epa.gov/ncct/>

